Two things happened to pharma search in the last eighteen months, and most brand teams have budgeted for neither.
The first is that the answer moved above the link. Google now resolves a large and growing share of health queries inside an AI Overview, before the user reaches a single result. Analysts at Gartner have predicted that traditional search engine volume will drop 25 percent by 2026 as users shift to AI chatbots and other virtual agents. The second is quieter and more dangerous: a clinician with a question is now as likely to open ChatGPT, Perplexity, or a medical answer engine like OpenEvidence as to open a browser. In a 2024 Wolters Kluwer survey, more than two-thirds of U.S. physicians (68 percent) said they now view generative AI as beneficial to healthcare, and adoption is running ahead of policy.
Put those together and the conclusion is uncomfortable. The unit of pharma visibility is no longer the ranked page. It is the sentence a machine speaks when someone asks about your therapy. That sentence is being assembled right now, from your label, your published data, third-party summaries, and whatever the model inferred to fill the gaps. Almost no pharma brand is watching it. That is the gap generative engine optimization in pharma is supposed to close, and the industry is arriving late.
Ranking was a position. Share of Answer is a paraphrase you do not control
SEO trained a generation of marketers to fight over position. You optimized a page, you earned a link, you watched a rank. The contest was legible because the artifact was fixed: your words, your page, your control.
Generative engine optimization breaks that contract. An answer engine does not hand the user your page. It reads many sources, including yours, and writes a new paragraph. The user reads the paragraph, not the source. So the question is no longer "where do I rank for this term." It is "when a clinician asks about this condition, how often does the machine mention my brand, and is what it says about my brand correct." That is Share of Answer, and it is the metric that replaces the ranking report.
Here is why this is harder than SEO ever was. A rank is something you can see. A paraphrase is something the model generates fresh, slightly differently, for every user, on every engine, and re-generates when the underlying model is updated. You cannot screenshot it once and call it monitored. The honest version of answer engine optimization in pharma is continuous measurement of a moving target, not a one-time audit. Treating it as a content-refresh project is the first mistake, and it is the one most brands are about to make.
Pharma is uniquely exposed, and not for the reason you would guess
Every industry is adapting to AI search. Pharma is the worst positioned to, and the obvious explanation, that it is slow and regulated, is only half right. The deeper problem is structural.
A travel brand that gets paraphrased badly loses a booking. A pharma brand that gets paraphrased badly can have a model state an indication the label does not support, drop a contraindication, or read a benefit off-label. The same paraphrasing freedom that makes answer engines useful is precisely what makes them a regulatory hazard for a regulated message. Your careful, MLR-approved language was engineered so that every clause survives scrutiny. The model was engineered to be fluent, which means to rephrase. Fluency and fidelity are in direct tension, and the model resolves that tension in favor of fluency every time.
It gets worse. The training data and retrieval sources for these models are thick with content you did not write and cannot edit: old press coverage, patient forums, competitor comparisons, summaries of trials that have since been superseded. When the model has a gap, it fills it from that ambient material, or it infers. A brand that has never said a word in the machine's vocabulary does not get silence. It gets a confident answer assembled from whatever was lying around. Saying nothing is not neutral. It is a decision to let the internet write your label summary.
And the function that should own this does not exist. MLR governs what you publish. Medical affairs governs the evidence. Brand governs the campaign. None of them has a mandate over what a third-party model says about the drug when no human from your company is in the room. That is the org-chart hole AEO in pharma falls straight through.
A worked example: what the machine already says about Varigel
Take a fictional brand, Varigel, approved for a single narrow indication with a known contraindication in patients on a common comorbidity medication. The label is precise. The MLR file is immaculate. Ask three different engines "what is Varigel used for" and you will, in practice, get three different paragraphs.
One engine answers cleanly and cites the label. Good. A second describes Varigel for the approved indication but also mentions, in a confident aside, a "commonly discussed" second use that appears in a years-old conference abstract the brand never promoted. That is off-label drift, generated, unprompted, and attached to your name. A third engine omits the contraindication entirely, because the source it leaned on summarized the efficacy data and skipped the safety section. None of this is malicious. All of it is the model doing exactly what it was built to do.
Now ask the question every brand should be able to answer and almost none can: how often does each of those three things happen, across the engines your audience actually uses, this week, and did it get better or worse after your last data readout? Without an instrument pointed at the machine, you are guessing. Worse, you are guessing about a regulatory exposure, in writing, that you cannot see.
Three moves every pharma brand should make now
You do not need a moonshot. You need to treat the machine's answer as a measurable surface and put three things in place.
1. Measure Share of Answer before you optimize anything. Pick the twenty questions your HCPs and patients actually ask, the real prompts, not your campaign headlines. Run them across the engines your audience uses: ChatGPT, Gemini, Perplexity, Google AI Overviews, Claude, and the medical answer engines in your therapeutic area. Record three numbers per question: are you mentioned, is the mention accurate against the label, and does anything read off-label. That baseline is your Share of Answer. Everything else is optimizing against a number you have not taken.
2. Feed the machine the approved sentence, in the structure it reads. Models reward sources that are clear, structured, attributable, and consistent. Your approved indication, your safety language, your evidence, expressed in plain, well-marked, machine-legible content, gives the engine a clean source to prefer over the ambient noise. This is the genuinely SEO-shaped part of GEO: not keyword stuffing, but making your correct answer the easiest correct answer for a model to lift. The catch is that the sentence you feed the machine has to be the approved one, which means the inside of your house has to be in order first.
3. Watch it continuously, and close the loop back to MLR. A baseline you take once is a screenshot of a river. When a model updates, when a competitor publishes, when a new abstract surfaces, the answer moves. The brands that win at answer engine optimization in pharma will be the ones that detect a new off-label drift the week it appears, trace it to a source, and route it to the people who can correct the underlying content. That requires the outside signal and the inside system to be joined, not sitting in two different tools owned by two different teams.
Where this leaves you
The reason most pharma brands cannot do the three moves above is not budget. It is that the inside and the outside have never been connected. The team that approves the message has no view of what the machine says. The agency that might watch the machine has no authority over the approved message. So drift is found late, by accident, in a screenshot someone forwards in alarm.
Juncture is built for exactly that seam. Inside, it pre-checks the approved message before MLR, comparing every asset against the label, surfacing how much of it reuses already-approved content, and backing the reviewer with a 21 CFR Part 11 trail and an e-signature sign-off. Outside, its Answer Monitor measures Share of Answer and off-label drift across the engines your audience uses, continuously, not once. The point is the join: the same approved sentence you cleared on the inside is the sentence Juncture watches for on the outside, so when the machine starts saying something the label does not support, you see it as a deviation from a known-good source, not as a surprise. Content reuse is the tangible payoff that funds the rest. You approve faster, you ship more from a smaller approved core, and the thing you shipped is the thing the machine learns to repeat.
Generative engine optimization in pharma is not a campaign you run next year. It is a measurement discipline you are already late to start. The brands that begin taking the baseline now will spend 2027 defending an answer they can see. The ones that wait will spend it explaining one they never knew they had.
Bring one brand and the twenty questions your audience actually asks. We will show you its Share of Answer today, flag the off-label drift already in the wild, and walk the line from that drift back to the approved sentence that should have been there. See it on your brand, then decide.
Sources
- Gartner, "Gartner Predicts Search Engine Volume Will Drop 25% by 2026, Due to AI Chatbots and Other Virtual Agents," February 2024. gartner.com
- Wolters Kluwer, "Over two-thirds of U.S. physicians have changed their mind, now viewing GenAI as beneficial in healthcare," 2024. wolterskluwer.com